Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it?https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

What is JAKne? (5.6.2022)

Save

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Read Article

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

Save

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article

Retrospective study of 71 adult-onset Still’s disease pts Rx 1st w/ High-dose glucocorticoids shows 41% failed to respond (poor outcome) by week4 w/ WBC as best predictor. If WBC < 13K 60% responded; if ≥13K only 23.5% https://t.co/tMNDgoqP14 https://t.co/xJrIEUU6iK

Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found.https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).https://t.co/sqsOHGThzV https://t.co/zeZrlDeQ9Z

52% of pediatric rheumatology patients do not make initial appointments or follow ups with adult rheumatology after 2 years of transfer of care! Dr. @hausmannMD #RNL2022 @RheumNow https://t.co/3lVxH1yqud

RheumNow Live is Coming to Town (3.11.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article

Single center study of individualized anakinra use in 47 autoinflammatory pts (32kids; 43% MAS; 40% systemic JIA). Off-label use in 38%, higher doses in 21 kids (5-29mg/kg); & 5 given IV anakinra; such doses were well tolerated without major AE. https://t.co/wQgw3YAPKX https://t.co/zL3HfdX4Ns

New Download Available! Autoimmune Disease in the USAhttps://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6

Tocilizumab Works Best in Non-Mechanical Ventilated COVID-19 Patients

Save

JAMA has published a meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, showing that a clinically meaningful mortality benefit from tocilizumab (and steroids) was best seen in those not requiring invasive mechanical ventilation (IMV).

Read Article

ICYMI: Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/P4SzIrWzYJ https://t.co/wnf3vnG4xc

When to suspect an interferonopathy (when suspected you should offer an autoinflammatory panel from https://t.co/F9bat3YS1d) #RWCS2022 @RWCSmtg Dr. Susan Shenoi https://t.co/qUts9X8gwJ

Dr Artie Kavanaugh presents comparison of targeted therapies in different inflammatory disorders. #RWCS2022 @RWCSmtg https://t.co/cX00RUOgAq

New 2021 JIA guidelines w 55 recommendations, 36 conditional and 19 strong. #RWCS2022 @RWCSmtg Dr Susan Shenoi https://t.co/CMETQeOdch

ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID

Save

A Task Force from the ACR has provided an updated (version 3) guidance for the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C), a COVID related condition characterized by fever, inflammation, and multiorgan dysfunction.

Read Article

UTSW Rheum Grand Rounds New and concerning: sJIA associated lung disease - rare and associated w/ pulmonary HTN, alveolar proteinosis, high mortality. Unique features: clubbing, eosinophilia, TCZ anaphylaxis, Trisomy 21. Most were Rx w/ IL-1 > IL-6 inhibition @UTSWRheum https://t.co/aJaPurDSmJ

UTSW Rheum Grand Rounds Treating STill's (sJIA) - early early use of anakinra yields best results (in remission and off steroids) - 91% if Anakinra started within the first 3 mos @UTSWRheum https://t.co/neozpYhJtM